Back

In vivo CRISPR screening identifies Fli1 as a transcriptional safeguard that restrains effector CD8 T cell differentiation during infection and cancer

Chen, Z.; Arai, E.; Khan, O.; Zhang, Z.; Ngiow, S. F.; He, Y.; Huang, H.; Manne, S.; Cao, Z.; Baxter, A. E.; Cai, Z.; Freilich, E.; Ali, M. A.; Giles, J. R.; Wu, J. E.; Greenplate, A. R.; Kurachi, M.; Nzingha, K.; Ekshyyan, V.; Wen, Z.; Speck, N. A.; Battle, A.; Berger, S. L.; Wherry, E. J.; Shi, J.

2020-05-20 immunology
10.1101/2020.05.20.087379 bioRxiv
Show abstract

Improving effector activity of antigen specific T cells is a major goal in cancer immunotherapy. Despite the identification of several effector T cell (TEFF)-driving transcription factors (TF), the transcriptional coordination of TEFF biology remains poorly understood. We developed an in vivo T cell CRISPR screening platform and identified a novel mechanism restraining TEFF biology through the ETS family TF, Fli1. Genetic deletion of Fli1 enhanced TEFF responses without compromising memory or exhaustion precursors. Fli1 restrained TEFF lineage differentiation by binding to cis-regulatory elements of effector-associated genes. Loss of Fli1 increased chromatin accessibility at ETS:RUNX motifs allowing more efficient Runx3-driven TEFF biology. CD8 T cells lacking Fli1 provided substantially better protection against multiple infections and tumors. These data indicate that Fli1 safeguards the developing CD8 T cell transcriptional landscape from excessive ETS:RUNX-driven TEFF cell differentiation. Moreover, genetic deletion of Fli1 improves TEFF differentiation and protective immunity in infections and cancer.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.